Review Article
Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
Table 3
Overview of main pharmacokinetic properties of NOACs.
| | | Dabigatran etexilate | Rivaroxaban | Apixaban |
| | Plasma peak (hours) | 1.5–3.0 | 2.0–4.0 | 3.0-4.0 |
| | Elimination half-life (hours) | 11–14: healthy volunteers
18–24: significantly impaired renal function | 5–9: healthy volunteers
11–13: elderly | 8–15: healthy volunteers |
| | Protein binding (%) | 35% | >90% | 87% |
| | Elimination (%) | 80% active renal
20% faecal | 33% non-active renal
66% metabolized: (metabolism: 50% renal and other half by hepatobiliary route) | Multiples pathways:
25%–29% renal
56% by faecal route |
| | Bioavailability | 3–7%
PH sensitive | 80–100% 10 mg
66%: 15–20 mg under fasting conditions | ±50% |
|
|
